Lindgaard SC, et al. - In two phase II trials, researchers tested the efficacy and safety of hepatic arterial treatment (HAT) for liver metastases in patients with metastatic breast cancer (MBC). They assessed capecitabine in combination with oxaliplatin. The treatment regimen was: continuous capecitabine (1300 mg/m²) was combined with oxaliplatin (85 mg/m²) alternating between systemic treatment and HAT followed by degradable starch microspheres with EmboCept S every second week. HAT was administered to overall 52 patients: 14 with liver metastases only and 38 patients with additional limited metastatic disease. A median of 2 (range 0–6) chemotherapeutic regimens for MBC were previously received by the participants. Findings revealed the safety as well as the effectiveness of HAT oxaliplatin in combination with capecitabine in patients with MBC. High response rates and a long median progression free and overall survival were observed, which were promising.